🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ryan D. Gentzler

University of Virginia Health System

ORCID: 0000-0002-8983-6677

Also affiliated with University of Virginia

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Papers

Driven by 10 papers — median percentile 0. Top paper: “Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial”.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00658-6
N/A
4.8DataRank · unranked
234 citations

Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji +32 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084
N/A
0.574DataRank · unranked
45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e20606
N/A
0.104DataRank · unranked
1 citations

Richard Piekarz, Liza C. Villaruz, John C. Rhee, W. Victoria Lai, Bethany J. Horton +7 more

Omics guided small molecule inhibitor screen for the identification of therapeutic vulnerabilities in metastatic lung adenocarcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e21015
N/A
0DataRank · unranked
0 citations

Lisa G. Gray, Ryan D. Gentzler, David R. Jones, Marty W. Mayo, Benjamin B. Morris

MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma

Frontiers in Oncology(2021)10.3389/fonc.2020.585551
N/A
0DataRank · unranked
18 citations

Nolan A. Wages, Patrick A. Grant, P. Todd Stukenberg, Ryan D. Gentzler, Richard D. Hall +9 more

A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9638
N/A
0DataRank · unranked
1 citations

Richard D. Hall, Andreas Saltos, Gregory A. Otterson, Ming Tan, Sacha Gnjatic +5 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336.v1
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.20.581048
N/A
0DataRank · unranked
1 citations

Nardin Ageeb, Joseph M. Obeid, Ileana S. Mauldin, Kate A. Goundry, Gabriel F. Hanson +9 more

Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.07.002
N/A
0DataRank · unranked
0 citations

Philip Young, Songzhu Zhao, Lai Wei, Sandip H. Patel, Mingjia Li +17 more